Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Ann Clin Microbiol Antimicrob ; 19(1): 22, 2020 May 30.
Article in English | MEDLINE | ID: mdl-32473652

ABSTRACT

A series of cases in the Northeast of the US during 2013-2015 described a new Borrelia species, Borrelia miyamotoi, which is transmitted by the same tick species that transmits Lyme disease and causes a relapsing fever-like illness. The geographic expansion of B. miyamotoi in the US also extends to other Lyme endemic areas such as the Midwestern US. Co-infections with other tick borne diseases (TBD) may contribute to the severity of the disease. On Long Island, NY, 3-5% of ticks are infected by B. miyamotoi, but little is known about the frequency of B. miyamotoi infections in humans in this particular region. The aim of this study was to perform a chart review in all patients diagnosed with B. miyamotoi infection in Stony Brook Medicine (SBM) system to describe the clinical and epidemiological features of B. miyamotoi infection in Suffolk County, NY. In a 5 year time period (2013-2017), a total of 28 cases were positive for either IgG EIA (n = 19) or PCR (n = 9). All 9 PCR-positive cases (median age: 67; range: 22-90 years) had clinical findings suggestive of acute or relapsing infection. All these patients were thought to have a TBD, prompting the healthcare provider to order the TBD panel which includes a B. miyamotoi PCR test. In conclusion, B. miyamotoi infection should be considered in the differential diagnosis for flu-like syndromes during the summer after a deer tick bite and to prevent labeling a case with Lyme disease.


Subject(s)
Borrelia Infections/diagnosis , Borrelia Infections/epidemiology , Borrelia/isolation & purification , Tick-Borne Diseases/diagnosis , Tick-Borne Diseases/epidemiology , Adult , Aged , Aged, 80 and over , Animals , Antibodies, Bacterial/blood , Borrelia/genetics , Borrelia Infections/complications , Coinfection , Female , Humans , Immunoglobulin G/blood , Immunoglobulin M/blood , Ixodes/microbiology , Lyme Disease , Male , Middle Aged , New York , Recombinant Proteins/immunology , Retrospective Studies , Tick-Borne Diseases/complications , Young Adult
2.
Obstet Gynecol ; 107(5): 977-83, 2006 May.
Article in English | MEDLINE | ID: mdl-16648399

ABSTRACT

OBJECTIVE: When 2 maternal deaths due to hemorrhage occurred at New York Hospital Queens in 2000-2001, a multidisciplinary team implemented systemic change. Our objective was to improve outcomes of episodes of major obstetric hemorrhage. METHODS: We report outcomes before (2000-2001) and after (2002-2005) the introduction of a patient safety program aimed at improving the care of women with major obstetric hemorrhage. Process changes were instituted in late 2001 at the direction of a multidisciplinary patient safety team. A rapid response team was formulated using the cardiac arrest team as a model. Protocols for early diagnosis, assessment, and management of patients at high risk for major obstetric hemorrhage were developed and communicated to staff. RESULTS: There were significant increases in cesarean births (P < .001), repeat cesarean births (P = .002), and cases of major obstetric hemorrhage (P = .02) between the periods of 2000-2001 and 2002-2005. There was a significant improvement in mortality due to hemorrhage (P = .036), lowest pH (P = .004), and lowest temperature (P < .001) when comparing 2000-2001 with 2002-2005. There were no differences in measures of severity of obstetric hemorrhage between the 2 periods, including Acute Physiology and Chronic Health Evaluation II scores, occurrence of placenta accreta and estimated blood loss. CONCLUSION: Despite a significant increase in major obstetric hemorrhage cases, we found improved outcomes and fewer maternal deaths after implementing systemic approaches to improve patient safety. Attention to improving the hospital systems necessary for the care of women at risk for major obstetric hemorrhage is important in the effort to decrease maternal mortality from hemorrhage.


Subject(s)
Critical Pathways/organization & administration , Obstetrics and Gynecology Department, Hospital/organization & administration , Patient Care Team/organization & administration , Postpartum Hemorrhage/therapy , Adult , Cesarean Section , Female , Humans , Hysterectomy , Postpartum Hemorrhage/etiology , Postpartum Hemorrhage/mortality , Practice Guidelines as Topic , Pregnancy , Retrospective Studies , Risk Factors , Severity of Illness Index , Treatment Outcome
3.
Crit Pathw Cardiol ; 3(2): 62-7, 2004 Jun.
Article in English | MEDLINE | ID: mdl-18340141

ABSTRACT

Perioperative cardiac ischemia and infarction are important causes of morbidity and mortality in patients undergoing noncardiac surgery. There is now significant evidence that the use of prophylactic beta-adrenergic antagonists among selected patients at risk for perioperative cardiovascular complications is associated with a reduction in myocardial ischemia and cardiac events. Furthermore, consensus guidelines have incorporated the findings of recent studies and provide recommendations for the appropriate utilization of beta-adrenergic antagonists among selected patients. Despite these guidelines, it is unknown to what extent these recommendations have become translated into clinical practice. After measuring perioperative beta-blocker use among participating hospitals within the New York Presbyterian Health Network, we developed a multicenter educational intervention to improve the overall utilization of beta-adrenergic prophylactic therapy in accordance with best practice guidelines. The literature supporting the development of this intervention is presented in this paper, along with the tools that are currently being used for decision support across an academic healthcare network.

SELECTION OF CITATIONS
SEARCH DETAIL
...